This is a study of the drug perifosine in combination with Gemcitabine. Perifosine is an oral
anti-cancer agent that has been used in more than 140 people, but has not been combined with
other drugs before this study. The study is designed to determine the highest dose of
perifosine that can be administered to people every day while they are on a Gemcitabine
regimen, without severe or prolonged nausea, vomiting and diarrhea. This study starts with
patients taking 50 mg/day and goes up to 150 mg/day. After the highest tolerable dose is
found, we will add 10 more patients at that dose.